Proliferative changes in chemoprevention trials: learning from secondary endpoints.
Szabo
Eva
E
D000077556:Alitretinoin; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D001980:Bronchi / Q000187:drug effects* / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects*; D018890:Chemoprevention / Q000379:methods; D023381:Endpoint Determination; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D019394:Ki-67 Antigen / Q000378:metabolism*; D011237:Predictive Value of Tests; D011379:Prognosis; D020545:Respiratory Mucosa / Q000187:drug effects* / Q000276:immunology; D014212:Tretinoin / Q000627:therapeutic use; D024502:alpha-Tocopherol / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D015415:Biomarkers; D019394:Ki-67 Antigen; D000077556:Alitretinoin; D014212:Tretinoin; D015474:Isotretinoin; D024502:alpha-Tocopherol